3 Specialty Chemicals Maker, Generic Medicines Company and CNC Machines Maker Stocks With a Strong Future Roadmap: Acutaas Chemicals, Caplin Point Laboratories and Jyoti CNC Automation
- November 18, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Acutaas Chemicals, Caplin Point Laboratories and Jyoti CNC Automation: ROE of 16.8% to 21.5% and FY22 to FY26 revenue CAGR of 15.2% to 30.2%. Prices as of 17 Nov 2026.
Quick Answer
The three specialty chemical, generic drug and CNC stocks to watch are Acutaas Chemicals, Caplin Point Laboratories and Jyoti CNC Automation. Their return on equity ranges from 16.8% to 21.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.2% to 30.2%. Acutaas Chemicals has the highest return on equity at 21.5%, while Jyoti CNC Automation has the fastest revenue growth at 30.2% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
Specialty chemical, generic drug and CNC stocks bring together companies with a visible plan for the years ahead. Acutaas Chemicals, Caplin Point Laboratories and Jyoti CNC Automation cover a specialty chemicals maker, a generic medicines company and a CNC machines maker.
This list covers three specialty chemical, generic drug and CNC stocks with complete current figures: Acutaas Chemicals, Caplin Point Laboratories and Jyoti CNC Automation. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Specialty Chemical, Generic Drug and CNC Stocks?
Specialty chemical, generic drug and CNC stocks are listed companies that make specialty and pharma chemicals for global clients, make generic medicines for Latin America and other markets, and make CNC machining centres for auto, aerospace and defence makers. Their earnings depend on chemical orders, medicine demand and machine tool orders.
Specialty Chemical, Generic Drug and CNC Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Acutaas Chemicals | 3,942.9 | 31,066 | 70.8 | 36.2 | 21.5 | 0.02 |
| Caplin Point Laboratories | 2,247.1 | 17,194 | 25.4 | 36.0 | 17.9 | 0.00 |
| Jyoti CNC Automation | 1,041.25 | 22,175 | 68.9 | 44.4 | 16.8 | 0.43 |
On valuation, Caplin Point Laboratories trades at a P/E below the industry P/E, while Acutaas Chemicals and Jyoti CNC Automation trade above it, which reflects the growth the market already expects. Readers comparing specialty chemical, generic drug and CNC stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Specialty Chemical, Generic Drug and CNC Stocks Have a Strong Roadmap in India?
Specialty chemical, generic drug and CNC stocks have a strong roadmap in India because wider global sourcing of specialty chemicals, steady demand for generic medicines and rising factory automation keep widening the market for these companies.
- Specialty chemicals. Global firms source from Indian plants.
- Generic medicines. Patients need affordable treatment.
- CNC machines. Factories automate precision work.
Why Acutaas Chemicals Features Among These Specialty Chemical, Generic Drug and CNC Stocks
Among the specialty chemical, generic drug and CNC stocks on this list, Acutaas Chemicals, earlier known as Ami Organics, is a Surat-based speciality chemicals company that makes advanced pharmaceutical intermediates, battery electrolyte additives and active ingredients for global customers.
The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2.
Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%.
Roadmap: The company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.
What to watch: Follow capacity additions, new product approvals and export orders.
Why Caplin Point Laboratories Features Among These Specialty Chemical, Generic Drug and CNC Stocks
Among the API intermediates, Latin America pharma and machine tool shares on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.
Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%.
In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.
Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.
What to watch: Follow new US product approvals and currency trends in Latin American markets.
Why Jyoti CNC Automation Features Among These Specialty Chemical, Generic Drug and CNC Stocks
Among the three companies on this list, Jyoti CNC Automation, based in Rajkot, makes computer numerical control machines, including multi-axis machining centres, for aerospace, defence, auto and general engineering customers.
In the June 2026 quarter, revenue grew 19.0% year on year to Rs 512 crore. Revenue rose from Rs 750 crore in FY22 to Rs 2,154 crore in FY26, a compound annual growth rate of 30.2%.
Net profit grew from Rs 151 crore in FY24 to Rs 336 crore in FY26, which works out to a compound annual growth rate of 49.2%. The company has a return on equity of 16.8%, a debt to equity ratio of 0.43 and a market capitalisation of Rs 22,175 crore. The stock trades at a P/E of 68.9, above the industry P/E of 44.4.
Roadmap: Defence and aerospace manufacturing, along with the shift to precision machining at Indian factories, supports demand for advanced CNC machines. The company has also built a presence in Europe through an acquisition, adding technology and customers abroad.
What to watch: Watch order book trends and how quickly the international business contributes.
Acutaas Chemicals vs Caplin Point Laboratories vs Jyoti CNC Automation on Key Financials
The table below sets the three specialty chemical, generic drug and CNC stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Acutaas Chemicals | 523 | 1,381 | 27.5% | 356 | 25.8% |
| Caplin Point Laboratories | 1,308 | 2,303 | 15.2% | 650 | 28.2% |
| Jyoti CNC Automation | 750 | 2,154 | 30.2% | 336 | 15.6% |
Acutaas Chemicals posts the highest return on equity in this group at 21.5%. Caplin Point Laboratories has the largest FY26 revenue at Rs 2,303 crore, and Jyoti CNC Automation shows the fastest revenue growth with a 30.2% compound annual rate. A useful habit with specialty chemical, generic drug and CNC stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Specialty Chemical, Generic Drug and CNC Stocks
Every theme carries risks that deserve a check before any decision. For these specialty chemical, generic drug and CNC stocks, the main points are: Long-term API intermediates, Latin America pharma and machine tool shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Raw material and energy costs. Input prices can move margins in chemicals.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Order timing. Project awards can shift between periods.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter specialty chemical, generic drug and CNC stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Specialty Chemical, Generic Drug and CNC Stocks
Specialty chemical, generic drug and CNC stocks suit investors who prefer to study business strength before price moves. Acutaas Chemicals, Caplin Point Laboratories and Jyoti CNC Automation each have a clear plan to grow. Based on the 17 November 2026 close, Acutaas Chemicals trades at Rs 3,942.9, Caplin Point Laboratories at Rs 2,247.1 and Jyoti CNC Automation at Rs 1,041.25. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these specialty chemical, generic drug and CNC stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track specialty chemical, generic drug and CNC stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are specialty chemical, generic drug and CNC stocks?
Ans. Specialty chemical, generic drug and CNC stocks are listed companies that make specialty and pharma chemicals for global clients, make generic medicines for Latin America and other markets, and make CNC machining centres for auto, aerospace and defence makers. Their earnings depend on chemical orders, medicine demand and machine tool orders. This list looks at three of them, Acutaas Chemicals, Caplin Point Laboratories and Jyoti CNC Automation, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which specialty chemical, generic drug and CNC stocks are covered in this list?
Ans. This list covers Acutaas Chemicals, Caplin Point Laboratories and Jyoti CNC Automation. Based on the 17 November 2026 close, Acutaas Chemicals traded at Rs 3,942.9, Caplin Point Laboratories at Rs 2,247.1 and Jyoti CNC Automation at Rs 1,041.25. Their return on equity ranges from 16.8% to 21.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 15.2% to 30.2%.
Why do specialty chemical, generic drug and CNC stocks have a strong future roadmap in India?
Ans. Specialty chemical, generic drug and CNC stocks have a strong roadmap in India because wider global sourcing of specialty chemicals, steady demand for generic medicines and rising factory automation keep widening the market for these companies. The main drivers are as follows. Specialty chemicals. Global firms source from Indian plants. Generic medicines. Patients need affordable treatment. CNC machines. Factories automate precision work. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Acutaas Chemicals performed financially?
Ans. Revenue rose from Rs 523 crore in FY22 to Rs 1,381 crore in FY26, a compound annual growth rate of 27.5%. Net profit grew from Rs 72.0 crore in FY22 to Rs 356 crore in FY26, which works out to a compound annual growth rate of 49.2%. The company has a return on equity of 21.5%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 31,066 crore. The stock trades at a P/E of 70.8, above the industry P/E of 36.2. Looking ahead, the company is expanding its range of advanced intermediates and building new capacity for battery materials and innovator pharma supply. Long-term supply relationships with global customers support its order flow.
How has Caplin Point Laboratories performed financially?
Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.
How has Jyoti CNC Automation performed financially?
Ans. Revenue rose from Rs 750 crore in FY22 to Rs 2,154 crore in FY26, a compound annual growth rate of 30.2%. Net profit grew from Rs 151 crore in FY24 to Rs 336 crore in FY26, which works out to a compound annual growth rate of 49.2%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 512 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.43 and a market capitalisation of Rs 22,175 crore. The stock trades at a P/E of 68.9, above the industry P/E of 44.4. Looking ahead, defence and aerospace manufacturing, along with the shift to precision machining at Indian factories, supports demand for advanced CNC machines. The company has also built a presence in Europe through an acquisition, adding technology and customers abroad.
What risks should investors check before buying specialty chemical, generic drug and CNC stocks?
Ans. Investors should check a few risks before buying specialty chemical, generic drug and CNC stocks. Raw material and energy costs. Input prices can move margins in chemicals. Regulatory approvals. Plant inspections and approvals can affect supplies. Order timing. Project awards can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of specialty chemical, generic drug and CNC stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.